Table 1.
Patient Baseline Characteristics at Study Entry
| Demographic Characteristic | All Patients (N = 15,942) | Fully Vaccinated (n = 12,403) | Partially Vaccinated (n = 480) | Unvaccinated (n = 3,059) | P |
|---|---|---|---|---|---|
| Age, y | 63 ± 15 | 64 ± 14 | 61 ± 15 | 59 ± 16 | <0.001 |
| Age ≥65 y | 7,785 (49%) | 6,379 (51%) | 207 (43%) | 1,199 (39%) | <0.001 |
| Age category | <0.001 | ||||
| <55 y | 4,293 (27%) | 2,952 (24%) | 156 (32%) | 1,185 (39%) | |
| 55-64 y | 3,864 (24%) | 3,072 (25%) | 117 (24%) | 675 (22%) | |
| 65-74 y | 4,443 (28%) | 3,613 (29%) | 119 (25%) | 701 (23%) | |
| ≥75 y | 3,352 (21%) | 2,766 (22%) | 88 (18%) | 498 (16%) | |
| Female sex | 6,708 (42%) | 5,114 (41%) | 224 (47%) | 1,370 (45%) | <0.001 |
| Race and ethnicity | <0.001 | ||||
| Non-Hispanic Black | 5,586 (35%) | 4,294 (35%) | 183 (38%) | 1,109 (36%) | |
| Hispanic | 968 (6%) | 801 (6%) | 20 (4%) | 147 (5%) | |
| Other | 1,083 (7%) | 925 (7%) | 21 (4%) | 137 (4%) | |
| Unknown | 1,400 (9%) | 1,027 (8%) | 51 (11%) | 322 (11%) | |
| Non-Hispanic White | 6,905 (43%) | 5,356 (43%) | 205 (43%) | 1,344 (44%) | |
| Dialysis vintage, mo | 43 ± 56 | 44 ± 56 | 38 ± 51 | 42 ± 56 | 0.01 |
| BMI, kg/m2 | 29 ± 8 | 29 ± 8 | 30 ± 8 | 29 ± 8 | 0.06 |
| Congregate livinga | 638 (4%) | 510 (4%) | 19 (4%) | 109 (4%) | 0.4 |
| Home dialysis | 1,953 (13%) | 1,571 (13%) | 40 (9%) | 342 (12%) | 0.02 |
| Peritoneal dialysis | 1,821 (12%) | 1,465 (12%) | 38 (8%) | 318 (11%) | |
| Home hemodialysis | 132 (1%) | 106 (1%) | 2 (1%) | 24 (1%) | |
| Adequate dialysis doseb | 13,729 (90%) | 10,962 (91%) | 388 (85%) | 2,379 (87%) | <0.001 |
| Serum albumin, g/dL | 3.8 ± 0.5 | 3.8 ± 0.4 | 3.7 ± 0.5 | 3.7 ± 0.5 | <0.001 |
| HBV seroimmunityc | 8,921 (58%) | 7,196 (59%) | 242 (52%) | 1,483 (53%) | <0.001 |
| Potential immunosuppression | 4,066 (26%) | 3,190 (26%) | 120 (26%) | 756 (27%) | 0.8 |
| Immune-modulating medications | 2,166 (14%) | 1,689 (14%) | 64 (14%) | 413 (15%) | 0.6 |
| Prior transplant | 1,096 (7%) | 879 (7%) | 24 (5%) | 193 (7%) | 0.2 |
| Immunodeficiency disorder | 2,880 (19%) | 2,273 (19%) | 81 (18%) | 526 (19%) | 0.8 |
| Disability | 599 (4%) | 461 (4%) | 27 (6%) | 111 (4%) | 0.08 |
| Tobacco use | 1,602 (10%) | 1,195 (10%) | 66 (14%) | 341 (12%) | <0.001 |
| Alcohol abuse disorder | 491 (3%) | 375 (3%) | 27 (6%) | 89 (3%) | 0.004 |
| Drug abuse disorder | 382 (3%) | 257 (2%) | 19 (4%) | 106 (4%) | <0.001 |
| No. of comorbidities | 2.9 ± 1.8 | 2.9 ± 1.8 | 3.1 ± 1.9 | 2.8 ± 1.8 | 0.003 |
| Diabetes mellitus | 8,860 (57%) | 7,101 (58%) | 288 (62%) | 1,471 (52%) | <0.001 |
| Hypertension | 12,266 (80%) | 9,689 (80%) | 357 (77%) | 2,220 (79%) | 0.2 |
| CHF | 3,138 (20%) | 2,394 (20%) | 117 (25%) | 627 (22%) | <0.001 |
| COPD | 2,138 (14%) | 1,668 (14%) | 67 (15%) | 403 (14%) | 0.7 |
| Stroke/cerebrovascular disorder | 1,270 (8%) | 992 (8%) | 45 (10%) | 233 (8%) | 0.5 |
| PVD | 1,767 (11%) | 1,400 (12%) | 60 (13%) | 307 (11%) | 0.4 |
| Thyroid disorder | 2,107 (13%) | 1,690 (14%) | 52 (11%) | 365 (12%) | 0.01 |
| History of cancer | 1,483 (10%) | 1,193 (10%) | 48 (9%) | 242 (9%) | 0.1 |
Results presented as count (%) or mean ± SD. Patients are grouped based on their vaccination status at the end of follow-up. “Unvaccinated” includes patients who never received a vaccine or recipients of a single dose of a vaccine ≤14 days earlier; “partially vaccinated” includes patients who had received the first mRNA vaccine dose ≥14 days earlier but the second dose <14 days earlier; “fully vaccinated” includes all patients whose last vaccine dose was ≥14 days earlier. For the table, categories are mutually exclusive. Abbreviations: BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HBV, hepatitis B virus; PVD, peripheral vascular disease.
Residing in nursing home or long-term care facility.
Adequate dialysis defined by hemodialysis single-pool Kt/V ≥1.2 or peritoneal dialysis weekly Kt/V ≥1.7.
HBV seroimmunity defined as hepatitis B surface antibody ≥10 mIU/mL.